PHBI (Pharmagreen Biotech) LT-Debt-to-Total-Asset: 0.86 (As of Jun. 2023)


What is Pharmagreen Biotech LT-Debt-to-Total-Asset?

Pharmagreen Biotech PHBI LT-Debt-to-Total-Asset is 0.86 as of Jun. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pharmagreen Biotech's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.86.

Pharmagreen Biotech's long-term debt to total assets ratio increased from Jun. 2022 (0.72) to Jun. 2023 (0.86). It may suggest that Pharmagreen Biotech is progressively becoming more dependent on debt to grow their business.

Pharmagreen Biotech  (OTCPK:PHBI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pharmagreen Biotech LT-Debt-to-Total-Asset Related Terms

Pharmagreen Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Pharmagreen Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmagreen Biotech LT-Debt-to-Total-Asset Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.12 0.11 0.57

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.57 0.43 0.56 0.86

Pharmagreen Biotech LT-Debt-to-Total-Asset Calculation

Pharmagreen Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (A: Sep. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2022 )/Total Assets (A: Sep. 2022 )
=0.119/0.209
=

Pharmagreen Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )/Total Assets (Q: Jun. 2023 )
=0.12/0.14
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.86 mean?
Pharmagreen Biotech (PHBI) has a LT-Debt-to-Total-Asset of 0.86 as of Jun. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's LT-Debt-to-Total-Asset too high?
Pharmagreen Biotech's current LT-Debt-to-Total-Asset is 0.86.
How does Pharmagreen Biotech's LT-Debt-to-Total-Asset compare to DVLP and CSTF?
Pharmagreen Biotech's LT-Debt-to-Total-Asset of 0.86 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pharmagreen Biotech and its competitors. Pharmagreen Biotech's current LT-Debt-to-Total-Asset is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current LT-Debt-to-Total-Asset of 0.86. The current LT-Debt-to-Total-Asset is 0.86. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current LT-Debt-to-Total-Asset is 0.86 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.